SCHEMBL4474982

SCHEMBL4474982

COc1cc(NC(=O)c2cccc(C(F)(F)F)c2)cc(C(N)=O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.65
KDM4E B2RXH2 6/20 0.65
MITF O75030 1/20 0.62
P2RX1 P51575 1/20 0.61
NPC1 O15118 1/20 0.59
POLB P06746 2/20 0.59
HTT P42858 1/20 0.59
MDM2 Q00987 1/20 0.59
HKDC1 Q2TB90 1/20 0.59
SAE1 Q9UBE0 1/20 0.59
UBA2 Q9UBT2 1/20 0.59
GAA P10253 1/20 0.59
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TAS1R3 Q7RTX0 1/20 0.58
TAS1R1 Q7RTX1 1/20 0.58
TAS1R2 Q8TE23 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464990 0.87 MAPT (0.66) MAPTKDM4EMITFNPC1POLB
SCHEMBL4474988 0.87 PTGS1 (0.67) MAPTKDM4EP2RX1POLBHTT
SCHEMBL17537390 0.86 MEN1 (0.69) MAPTKDM4EP2RX1NPC1HTT
SCHEMBL20467556 0.83 P2RX1 (0.60) MAPTKDM4EP2RX1NPC1HTT
SCHEMBL31060524 0.82 MAPT (0.76) MAPTP2RX1POLBHTTRXFP1
SCHEMBL4462072 0.82 MAPT (0.76) MAPTP2RX1POLBHTTRXFP1
SCHEMBL5350952 0.78 MAPT (0.72) MAPTP2RX1POLBHTTRXFP1
SCHEMBL4464994 0.78 MAPT (0.69) MAPTKDM4EMITFNPC1POLB
SCHEMBL4476633 0.77 MAPT (0.86) MAPTP2RX1POLBHTTRXFP1
SCHEMBL5227631 0.77 P2RX1 (1.00) MAPTP2RX1POLBHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US claimed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US claimed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US disclosed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US disclosed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP disclosed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors AURKC, PTK2B, FRK MAPT 1523/4885KDM4E 2272/4885MITF 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.